sur Laxxon Medical
Laxxon Medical to Showcase LXM.2, a Novel 3D Printed GLP-1 Agonist at BIO 2024
Laxxon Medical, a US-based pharma-technology company, revealed plans to demonstrate its innovative LXM.2 asset at the BIO International Convention scheduled for June 3-6, 2024 in San Diego. The company is focusing on utilizing its novel 3D printing technology, SPID®, for this upcoming presentation.
The BIO International Convention, recognized as the world's largest biotech event, draws over 20,000 industry leaders annually, offering extensive networking prospects and opportunities for new partnerships.
LXM.2, designed as a once-a-day oral treatment for weight loss, integrates a GLP-1 agonist with a permeation enhancer via SPID® to enhance bioavailability. Laxxon aims to expedite LXM.2's development through the 505(b)2 pathway and seeks collaboration for out-licensing or co-development at the event.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Laxxon Medical